Blood Cancers
Advertisement
Researchers found that Hispanic people were more likely to develop and die from ALL than Black and White people.
Hispanic patients with multiple myeloma had lower overall response rates to idecabtagene vicleucel.
Advanced age, financial constraints contribute to higher discontinuation rates among elderly Medicare beneficiaries.
Breastfeeding has a protective effect against acute lymphoblastic leukemia in young children.
Study suggests significant associations between nonchromosomal birth defects and childhood leukemia.
Vitamin C and D supplementation for the treatment of AML, was associated with reduced infection rates.
Modifying or ceasing MM treatment based on negative MRD status may be a promising approach for newly diagnosed patients.
White patients with MM and diabetes showed worse survival outcomes, but this association was not found in Black patients.
Phase 1 data showed promising outcomes with elranatamab in MM, and authors recommend a phase 2 dose of 76 mg weekly.
Patients with MM and renal impairment on DVd showed safety and efficacy comparable with patients without renal impairment.
The prognosis for induction failure in childhood T-cell ALL remains unfavorable despite advancements in treatment.
Higher creatinine levels and decompression surgery without fusion were linked to complications after spinal surgery in MM.
The phase 1/2 MajesTEC-1 study established a recommended dose for subcutaneous teclistamab in relapsed or refractory MM.
Prior allogeneic stem cell transplantation did not appear to impact the safety and efficacy of cilta-cel treatment for MM.
Being overweight or obese was associated with increased toxicity and higher nonrelapse mortality.
Sociodemographic factors lead to disparities in outcomes for multiple myeloma patients.
IMWG multiple myeloma treatment guidelines informed by studies with a major lack of Black patients, study finds.
Researchers discovered that breast cancer survivors had a heightened risk of being diagnosed with pericarditis.
The insurance status of patients with AML impacted access to molecular genetic sequencing and overall survival.
Daratumumab added to carfilzomib-lenalidomide-dexamethasone triplet therapy for multiple myeloma improved MRD and survival.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.